This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Regeneron Gains on Eylea, Dupixent and Pipeline Progress
by Zacks Equity Research
Solid performance of approved drugs like Eylea and Dupixent along with an encouraging pipeline progress improve Regeneron's (REGN) market position.
Regeneron-Sanofi Report Data on Dupixent in Atopic Dermatitis
by Zacks Equity Research
Regeneron (REGN) and partner Sanofi present encouraging data from a late-stage trial on dermatitis drug Dupixent in adolescents.
Is Artificial Intelligence the Next Big Thing in Biotech?
by Kinjel Shah
Artificial intelligence can drastically reduce the time taken to develop new life-saving drugs.
Pharma/Biotech Stocks to Watch This Prostate Cancer Month
by Zacks Equity Research
Here we highlight a few companies that are focused on developing treatments for prostate cancer.
Biotech Stock Roundup: GILD's Arthritis Drug Successful in Phase III, PRQR Soars
by Zacks Equity Research
Pipeline updates and collaborating agreement comprise some of the key developments in the biotech sector this week.
Regeneron/Sanofi's sBLA for Praluent to be Reviewed by FDA
by Zacks Equity Research
The FDA will review Regeneron (REGN) and Sanofi's sBLA for its PCSK9 Inhibitor Praluent to reduce risk of major adverse cardiovascular events.
Pharma Stock Roundup: NVS' Sandoz Deal, Pipeline Updates at AZN & Others in Focus
by Zacks Equity Research
Novartis (NVS) to sell parts of its Sandoz Unit. AstraZeneca (AZN), Merck (MRK), Pfizer (PFE) and others announce pipeline and regulatory updates.
Alnylam's Shares Up as Onpattro Gets FDA and EU Approvals
by Zacks Equity Research
Shares of Alnylam (ALNY) increase due to the FDA and European approval for Onpattro.
Sanofi's Blood Disorder Drug Cablivi Gets Approval in Europe
by Zacks Equity Research
Sanofi's (SNY) Cablivi receives approval for the treatment of acquired thrombotic thrombocytopenic purpura, a rare blood clotting disorder.
Alnylam Gets European Nod for First-Ever RNAi Therapeutic
by Zacks Equity Research
Alnylam's (ALNY) Onpattro, the first ever RNA interference (RNAi) therapeutic, has been granted marketing authorization by the European Commission.
The Zacks Analyst Blog Highlights: Visa, PNC, SAP, Sanofi and Ross
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Visa, PNC, SAP, Sanofi and Ross
Emergent (EBS) to Buy Narcan Maker Adapt Pharma for $735M
by Zacks Equity Research
Emergent (EBS) inks a deal to buy Adapt Pharma. This move will add the latter's popular Narcan nasal spray to its portfolio.
Top Research Reports for Visa, PNC Financial & SAP
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Visa (V), PNC Financial Services Group (PNC) and SAP SE (SAP)
Zai Lab Stock Down, Atopic Dermatitis Candidate Trial Fails
by Zacks Equity Research
Shares of Zai Lab (ZLAB) decline following the failure of a phase IIA study on its pipeline candidate, ZL-3101, for the treatment of atopic dermatitis.
Large-Cap Pharma Rebounds: 2 Stocks to Boost Your Portfolio
by Kinjel Shah
The large-cap pharma industry is on track to recovery. Here are two stocks from the space that investors may consider betting on.
Regeneron's Eylea Gets FDA Nod for Wet AMD as a 12-Week Dose
by Zacks Equity Research
Regeneron Pharmaceuticals (REGN) gets the FDA approval for the label expansion of its lead drug, Eylea as a treatment for wet AMD with a modified 12-week dosing schedule.
Regeneron, Teva Announce Positive Data on Osteoarthritis Drug
by Zacks Equity Research
Regeneron (REGN) along with partner Teva announces positive top-line results from a late-stage candidate on fasinumab in patients with chronic pain from osteoarthritis of the knee or hip.
Medtronic Unveils Inner CircleSM Program, Boosts Diabetes Arm
by Zacks Equity Research
Medtronic (MDT) focuses on initiatives to boost its diabetes business.
Regeneron's 12-Week Eylea Dose Gets CRL From FDA for Wet AMD
by Zacks Equity Research
Regeneron (REGN) suffers setback as the FDA issues a CRL to its application for label expansion of Eylea for wet AMD with a modified 12-week dosing schedule.
Alnylam (ALNY) Gets FDA Nod for First-Ever RNAi Therapeutic
by Zacks Equity Research
Alnylam (ALNY) receives FDA approval for Onpattro to treat polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults.
Amicus (FOLD) Gets FDA Nod for Fabry Disease Drug Galafold
by Zacks Equity Research
Amicus (FOLD) gets a major boost with the FDA approval of lead candidate, Galafold (migalastat) 123 mg capsules for the treatment of Fabry disease.
Roche's (RHHBY) Xolair Gets Breakthrough Therapy Status
by Zacks Equity Research
Genentech's, a subsidiary of Roche (RHHBY), allergy drug, Xolair, gets Breakthrough Therapy designation in the United States for the prevention of severe food allergic reactions.
Alnylam's (ALNY) Q2 Loss Wider Than Expected, Sales Beat
by Zacks Equity Research
Alnylam (ALNY) posted wider-than-expected loss in the second quarter of 2018 and received a positive opinion from the CHMP for the marketing authorization of patisiran.
Emergent (EBS) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Emergent Biosolutions (EBS) rides high on earnings as well as revenue beat in Q2.
The Zacks Analyst Blog Highlights: Pfizer, Bristol-Myers, Sanofi, Glaxo and Novartis
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Pfizer, Bristol-Myers, Sanofi, Glaxo and Novartis